Literature DB >> 9519098

One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol.

J C Speller1, T R Barnes, D A Curson, C Pantelis, J L Alberts.   

Abstract

BACKGROUND: Amisulpride is a potent substituted benzamide antipsychotic drug claimed to improve the negative symptoms of schizophrenia, particularly at low dosage.
METHOD: Sixty long-term in-patients with schizophrenia and selected for predominant negative symptoms were randomised to receive either haloperidol or amisulpride. Over a year there was systematic dose reduction, as symptoms allowed.
RESULTS: There were no significant differences between the treatment groups in the proportion receiving low-dose treatment, the control of positive symptoms, or ratings of social behaviour, side-effects or tardive dyskinesia. For negative symptoms, there were consistent but non-significant trends in favour of amisulpride. The amisulpride patients required significantly less anticholinergic medication.
CONCLUSIONS: In chronically-hospitalised in-patients with schizophrenia characterised by persistent negative symptoms, amisulpride was a well-tolerated maintenance antipsychotic medication. The drug had only a limited effect in reducing negative symptoms, which were relatively stable, enduring phenomena in this sample, despite dosage reduction.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9519098     DOI: 10.1192/bjp.171.6.564

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  22 in total

1.  Is the superior efficacy of new generation antipsychotics an artifact of LOCF?

Authors:  Stefan Leucht; Rolf R Engel; Josef Bäuml; John M Davis
Journal:  Schizophr Bull       Date:  2006-08-11       Impact factor: 9.306

Review 2.  [Pharmacotherapy for schizophrenia].

Authors:  W W Fleischhacker; W Hummer
Journal:  Nervenarzt       Date:  2006-11       Impact factor: 1.214

Review 3.  Persistent negative symptoms in schizophrenia: an overview.

Authors:  Robert W Buchanan
Journal:  Schizophr Bull       Date:  2006-11-10       Impact factor: 9.306

Review 4.  Antipsychotic medication for elderly people with schizophrenia.

Authors:  R G Marriott; W Neil; S Waddingham
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

5.  On the concept of remission in schizophrenia.

Authors:  Stefan Leucht; Romain Beitinger; Werner Kissling
Journal:  Psychopharmacology (Berl)       Date:  2007-07-06       Impact factor: 4.530

6.  Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features.

Authors:  Jonathan Rabinowitz; Stephen Z Levine; Orna Barkai; Ori Davidov
Journal:  Schizophr Bull       Date:  2008-02-26       Impact factor: 9.306

Review 7.  Spotlight on amisulpride in schizophrenia.

Authors:  Monique P Curran; Caroline M Perry
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 8.  Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis.

Authors:  Marc Krause; Yikang Zhu; Maximilian Huhn; Johannes Schneider-Thoma; Irene Bighelli; Adriani Nikolakopoulou; Stefan Leucht
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-01-24       Impact factor: 5.270

Review 9.  Tolerability of atypical antipsychotics.

Authors:  C Stanniland; D Taylor
Journal:  Drug Saf       Date:  2000-03       Impact factor: 5.606

10.  Update on the management of symptoms in schizophrenia: focus on amisulpride.

Authors:  Ann M Mortimer
Journal:  Neuropsychiatr Dis Treat       Date:  2009-05-20       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.